According to Science magazine, reprogrammed adult stem cells that regress to an embryonic state and have the same ability to transform into all the different tissues in the human body just like embryonic stem cells are the most important discovery of 2008. The prestigious magazine awarded the so-called ethical stem cells for their possible efficiency in curing degenerative diseases like Alzheimer’s, Parkinson’s, and muscular dystrophy without the ethical implications associated with embryonic stem cell use. The direct observation of extrasolar planets and the development of new superconductors were also in the ranking.
A spun 3-D scaffold of nanofibers did a better job of producing larger quantities of and a more durable type of the cartilage protein than flat, 2-D sheets of fibers did.
Johns Hopkins tissue engineers have used tiny, artificial fiber scaffolds thousands of times smaller than a human hair to help coax stem cells into developing into cartilage, the shock-absorbing lining of elbows and knees that often wears thin from injury or age.
Reporting online June 4 in the Proceedings of the National Academy of Sciences, investigators say they have produced an important component of cartilage in both laboratory
Image via Wikipedia
Stem cell therapy holds promise for the treatment of almost all human diseases, from spinal cord injuries to damage caused by heart attacks. Stem cells are the cells in our body that have the potential to “grow up” to be any type of cell in the body. But organs are more than just collections of cells. They’re highly organized collections of a multitude of cells.
All treatments with stems cells are still experimental, and therefore the risks of this treatment are not completely understood. Clinical trials are monitored in the United States by academic and government agencies to
Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson’s disease. The technique could be developed for application in other degenerative conditions.
Drs Clare Parish and Lachlan Thompson lead the research from the Florey Neuroscience Institutes and the University of Melbourne. They are members of the newly established Stem Cells Australia collaboration launched at the University of Melbourne today.
Stem Cells Australia is a new $21m Australian Research Council Special Research Initiative bringing together Australia’s leading stem cell scientists.
Led by internationally renowned stem cell expert Professor Martin Pera and administered by the
Emory University researchers have received approval from the Food and Drug Administration (FDA) to advance to the next phase of a landmark trial to treat patients with Amyotrophic Lateral Sclerosis (ALS) using human neural stem cells.
The Phase I trial, currently underway exclusively at Emory University, is designed to assess the safety of implanting neural stem cells into the spinal cord in up to 18 people with ALS and began in January 2010. The first 12 patients received neural stem cell transplants in the lumbar, or lower, region of the spinal cord. After reviewing safety data from these patients, the